Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.66 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918321 | 1.00 | HDAC1 (0.66) | HDAC1HDAC6HDAC2HDAC3HDAC8 | |
| SCHEMBL3917184 | 0.85 | HDAC1 (0.58) | HDAC1HDAC6HDAC2HDAC3HDAC8 | |
| SCHEMBL3917185 | 0.85 | HDAC1 (0.58) | HDAC1HDAC6HDAC2HDAC3HDAC8 | |
| SCHEMBL4569181 | 0.84 | HDAC1 (0.71) | HDAC1HDAC6HDAC2HDAC3HDAC8 | |
| SCHEMBL3919407 | 0.83 | HDAC1 (0.70) | HDAC1HDAC6HDAC2HDAC3HDAC8 | |
| SCHEMBL3919405 | 0.83 | HDAC1 (0.70) | HDAC1HDAC6HDAC2HDAC3HDAC8 | |
| SCHEMBL24392693 | 0.82 | HPGDS (0.70) | HDAC1HDAC2HDAC3NAMPTHPGDS | |
| SCHEMBL19631297 | 0.82 | HDAC6 (0.69) | HDAC1HDAC6HDAC2HDAC3HDAC8 | |
| SCHEMBL3581806 | 0.81 | RAB9A (0.71) | HDAC1HDAC6HDAC2HDAC3HDAC8 | |
| SCHEMBL3581803 | 0.81 | RAB9A (0.71) | HDAC1HDAC6HDAC2HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495022-B2 | α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2009-02-24 | — | — | US | disclosed |
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2005-06-09 | — | — | US | disclosed |
| WO-2003087066-A1 | α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | SK CHEMICALS, CO., LTD. (KR) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | HDAC1, HDAC5, HDAC9 | HDAC1 1/4885HDAC6 10/4885HDAC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.